Literature DB >> 19454606

Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort.

Guillermo J Pons-Estel1, Luis A González, Jie Zhang, Paula I Burgos, John D Reveille, Luis M Vilá, Graciela S Alarcón.   

Abstract

OBJECTIVE: To determine the features predictive of atherosclerotic cardiovascular damage in patients with SLE.
METHODS: SLE LUMINA (LUpus in MInorities: NAture vs nurture) patients (n = 637), aged >or=16 years, disease duration <or=5 years at baseline (T0), of African-American, Hispanic and Caucasian ethnicity were studied. Atherosclerotic cardiovascular damage was defined by the following items of the SLICC Damage Index (SDI) cardiovascular domain: angina or coronary artery by pass surgery, myocardial infarction and/or congestive heart failure; factors associated with its occurrence were examined by univariable and multivariable regression analyses.
RESULTS: Forty-three (6.8%) of 637 patients developed cardiovascular damage over a mean +/- S.D. total disease duration of 6.6 +/- 3.6 years. Nearly 90% of the patients were women with a mean +/- s.d. age of 36.5 (12.6) years; all ethnic groups were represented. By multivariable analyses, after adjusting for the cardiovascular manifestations present, age [odds ratio (OR) = 1.06; 95% CI 1.03, 1.09], male gender (OR = 3.57; 95% CI 1.35, 9.09) SDI at baseline (OR = 1.28; 95% CI 1.09, 1.50) and CRP levels [highest tertile (OR = 2.63; 95% CI 1.17, 5.91)] were associated with the occurrence of cardiovascular damage, whereas the number of years of education was negatively associated with such outcome (OR = 0.85; 95% CI 0.74, 0.94).
CONCLUSIONS: Our data suggest that atherosclerotic cardiovascular damage in SLE is multifactorial; traditional (age, gender) and disease-related factors (CRP levels, SDI at baseline) appear to be important contributors to such an occurrence. Tight control of the inflammatory process must be achieved to prevent it.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19454606      PMCID: PMC2722811          DOI: 10.1093/rheumatology/kep102

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  50 in total

1.  Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus.

Authors:  J M Esdaile; M Abrahamowicz; T Grodzicky; Y Li; C Panaritis; R du Berger; R Côte; S A Grover; P R Fortin; A E Clarke; J L Senécal
Journal:  Arthritis Rheum       Date:  2001-10

2.  A multicenter study of outcome in systemic lupus erythematosus. II. Causes of death.

Authors:  S Rosner; E M Ginzler; H S Diamond; M Weiner; M Schlesinger; J F Fries; C Wasner; T A Medsger; G Ziegler; J H Klippel; N M Hadler; D A Albert; E V Hess; G Spencer-Green; A Grayzel; D Worth; B H Hahn; E V Barnett
Journal:  Arthritis Rheum       Date:  1982-06

3.  The bimodal mortality pattern of systemic lupus erythematosus.

Authors:  M B Urowitz; A A Bookman; B E Koehler; D A Gordon; H A Smythe; M A Ogryzlo
Journal:  Am J Med       Date:  1976-02       Impact factor: 4.965

4.  Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus.

Authors:  P Rahman; M B Urowitz; D D Gladman; I N Bruce; J Genest
Journal:  J Rheumatol       Date:  1999-11       Impact factor: 4.666

5.  Damage in systemic lupus erythematosus and its association with corticosteroids.

Authors:  A Zonana-Nacach; S G Barr; L S Magder; M Petri
Journal:  Arthritis Rheum       Date:  2000-08

6.  Premature coronary-artery atherosclerosis in systemic lupus erythematosus.

Authors:  Yu Asanuma; Annette Oeser; Ayumi K Shintani; Elizabeth Turner; Nancy Olsen; Sergio Fazio; MacRae F Linton; Paolo Raggi; C Michael Stein
Journal:  N Engl J Med       Date:  2003-12-18       Impact factor: 91.245

7.  C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study.

Authors:  Aaron R Folsom; Nena Aleksic; Diane Catellier; Harinder S Juneja; Kenneth K Wu
Journal:  Am Heart J       Date:  2002-08       Impact factor: 4.749

8.  Immunology of DNA. III. Crithidia luciliae, a simple substrate for the determination of anti-dsDNA with the immunofluorescence technique.

Authors:  L A Aarden; E R de Groot; T E Feltkamp
Journal:  Ann N Y Acad Sci       Date:  1975-06-30       Impact factor: 5.691

9.  Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice.

Authors:  Haim D Danenberg; Alexander J Szalai; Rajesh V Swaminathan; Lin Peng; Zhiping Chen; Philip Seifert; William P Fay; Daniel I Simon; Elazer R Edelman
Journal:  Circulation       Date:  2003-07-21       Impact factor: 29.690

10.  C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice.

Authors:  Antoni Paul; Kerry W S Ko; Lan Li; Vijay Yechoor; Mark A McCrory; Alexander J Szalai; Lawrence Chan
Journal:  Circulation       Date:  2004-01-26       Impact factor: 29.690

View more
  30 in total

Review 1.  Cardiovascular comorbidity in rheumatic diseases: a focus on heart failure.

Authors:  Kerry Wright; Cynthia S Crowson; Sherine E Gabriel
Journal:  Heart Fail Clin       Date:  2014-01-10       Impact factor: 3.179

Review 2.  Pathogenesis and treatment of atherosclerosis in lupus.

Authors:  Maureen McMahon; Brian Skaggs
Journal:  Rheum Dis Clin North Am       Date:  2014-06-10       Impact factor: 2.670

Review 3.  Prevalence and burden of pediatric-onset systemic lupus erythematosus.

Authors:  Sylvia Kamphuis; Earl D Silverman
Journal:  Nat Rev Rheumatol       Date:  2010-08-03       Impact factor: 20.543

4.  Heart failure risk in systemic lupus erythematosus compared to diabetes mellitus and general medicaid patients.

Authors:  Sarah K Chen; Medha Barbhaiya; Michael A Fischer; Hongshu Guan; Kazuki Yoshida; Candace H Feldman; Karen H Costenbader; Brendan M Everett
Journal:  Semin Arthritis Rheum       Date:  2019-06-11       Impact factor: 5.532

5.  Management of cardiovascular complications in systemic lupus erythematosus.

Authors:  Carly Skamra; Rosalind Ramsey-Goldman
Journal:  Int J Clin Rheumtol       Date:  2010-02-01

6.  Five-Year Follow-Up of Coronary Microvascular Dysfunction and Coronary Artery Disease in Systemic Lupus Erythematosus: Results From a Community-Based Lupus Cohort.

Authors:  Vaneet K Sandhu; Janet Wei; Louise E J Thomson; Daniel S Berman; Jay Schapira; Daniel Wallace; Michael H Weisman; C Noel Bairey Merz; Mariko L Ishimori
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-06-04       Impact factor: 4.794

7.  Influence of chronic inflammation and autoimmunity on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients.

Authors:  Wojciech Plazak; Mieczyslaw Pasowicz; Magdalena Kostkiewicz; Jakub Podolec; Lidia Tomkiewicz-Pajak; Jacek Musial; Piotr Podolec
Journal:  Inflamm Res       Date:  2011-07-10       Impact factor: 4.575

8.  Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, double-masked, placebo-controlled study.

Authors:  Wojciech Plazak; Krzysztof Gryga; Hanna Dziedzic; Lidia Tomkiewicz-Pajak; Malgorzata Konieczynska; Piotr Podolec; Jacek Musial
Journal:  Arthritis Res Ther       Date:  2011-07-20       Impact factor: 5.156

9.  Comparative risks of cardiovascular disease events among SLE patients receiving immunosuppressive medications.

Authors:  May Y Choi; Daniel Li; Candace H Feldman; Kazuki Yoshida; Hongshu Guan; Seoyoung C Kim; Brendan M Everett; Karen H Costenbader
Journal:  Rheumatology (Oxford)       Date:  2021-08-02       Impact factor: 7.580

10.  Plasma osteopontin versus intima media thickness of the common carotid arteries in well-characterised patients with systemic lupus erythematosus.

Authors:  Lina Wirestam; Muna Saleh; Christina Svensson; Michele Compagno; Helene Zachrisson; Jonas Wetterö; Christopher Sjöwall
Journal:  Lupus       Date:  2021-05-06       Impact factor: 2.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.